185 related articles for article (PubMed ID: 38663337)
1. Minocycline and photodynamic priming significantly improve chemotherapy efficacy in heterotypic spheroids of pancreatic ductal adenocarcinoma.
Bano S; Alburquerque JQ; Roberts HJ; Pang S; Huang HC; Hasan T
J Photochem Photobiol B; 2024 Jun; 255():112910. PubMed ID: 38663337
[TBL] [Abstract][Full Text] [Related]
2. Impacting Pancreatic Cancer Therapy in Heterotypic
Obaid G; Bano S; Mallidi S; Broekgaarden M; Kuriakose J; Silber Z; Bulin AL; Wang Y; Mai Z; Jin W; Simeone D; Hasan T
Nano Lett; 2019 Nov; 19(11):7573-7587. PubMed ID: 31518145
[TBL] [Abstract][Full Text] [Related]
3. Photoimmunotherapy Retains Its Anti-Tumor Efficacy with Increasing Stromal Content in Heterotypic Pancreatic Cancer Spheroids.
Saad MA; Zhung W; Stanley ME; Formica S; Grimaldo-Garcia S; Obaid G; Hasan T
Mol Pharm; 2022 Jul; 19(7):2549-2563. PubMed ID: 35583476
[TBL] [Abstract][Full Text] [Related]
4. Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancreatic Cancer.
Obaid G; Bano S; Thomsen H; Callaghan S; Shah N; Swain JWR; Jin W; Ding X; Cameron CG; McFarland SA; Wu J; Vangel M; Stoilova-McPhie S; Zhao J; Mino-Kenudson M; Lin C; Hasan T
Adv Sci (Weinh); 2022 Aug; 9(24):e2104594. PubMed ID: 35748165
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy.
Anbil S; Pigula M; Huang HC; Mallidi S; Broekgaarden M; Baglo Y; De Silva P; Simeone DM; Mino-Kenudson M; Maytin EV; Rizvi I; Hasan T
Mol Cancer Ther; 2020 Jun; 19(6):1308-1319. PubMed ID: 32220968
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer.
Hu DX; Tang WL; Zhang Y; Yang H; Wang W; Agama K; Pommier Y; An LK
J Med Chem; 2021 Jun; 64(11):7617-7629. PubMed ID: 34008967
[TBL] [Abstract][Full Text] [Related]
7. A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent.
Thakar M; Hu Y; Morreale M; Lerner L; Ying Lin W; Sen R; Cai Y; Karunasena E; Thakar M; Saggi S; Keer H; Ahuja N
PLoS One; 2018; 13(6):e0199130. PubMed ID: 29927979
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).
Conda-Sheridan M; Reddy PV; Morrell A; Cobb BT; Marchand C; Agama K; Chergui A; Renaud A; Stephen AG; Bindu LK; Pommier Y; Cushman M
J Med Chem; 2013 Jan; 56(1):182-200. PubMed ID: 23259865
[TBL] [Abstract][Full Text] [Related]
9. Dual DNA topoisomerase 1 and tyrosyl-DNA phosphodiesterase 1 inhibition for improved anticancer activity.
Zakharenko A; Dyrkheeva N; Lavrik O
Med Res Rev; 2019 Jul; 39(4):1427-1441. PubMed ID: 31004352
[TBL] [Abstract][Full Text] [Related]
10. Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors.
Huang SN; Pommier Y; Marchand C
Expert Opin Ther Pat; 2011 Sep; 21(9):1285-92. PubMed ID: 21843105
[TBL] [Abstract][Full Text] [Related]
11. Size-dependent Tumor Response to Photodynamic Therapy and Irinotecan Monotherapies Revealed by Longitudinal Ultrasound Monitoring in an Orthotopic Pancreatic Cancer Model.
Pigula M; Huang HC; Mallidi S; Anbil S; Liu J; Mai Z; Hasan T
Photochem Photobiol; 2019 Jan; 95(1):378-386. PubMed ID: 30229942
[TBL] [Abstract][Full Text] [Related]
12. Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan.
Meisenberg C; Gilbert DC; Chalmers A; Haley V; Gollins S; Ward SE; El-Khamisy SF
Mol Cancer Ther; 2015 Feb; 14(2):575-85. PubMed ID: 25522766
[TBL] [Abstract][Full Text] [Related]
13. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.
Zhang XR; Wang HW; Tang WL; Zhang Y; Yang H; Hu DX; Ravji A; Marchand C; Kiselev E; Ofori-Atta K; Agama K; Pommier Y; An LK
J Med Chem; 2018 Nov; 61(22):9908-9930. PubMed ID: 30336023
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery.
Huang HC; Rizvi I; Liu J; Anbil S; Kalra A; Lee H; Baglo Y; Paz N; Hayden D; Pereira S; Pogue BW; Fitzgerald J; Hasan T
Cancer Res; 2018 Jan; 78(2):558-571. PubMed ID: 29187403
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
[TBL] [Abstract][Full Text] [Related]
16. Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma.
Deodhar S; Dash AK; North EJ; Hulce M
AAPS PharmSciTech; 2020 Aug; 21(6):231. PubMed ID: 32778980
[TBL] [Abstract][Full Text] [Related]
17. Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes.
Chen X; Yu Q; Liu Y; Sheng Q; Shi K; Wang Y; Li M; Zhang Z; He Q
Acta Biomater; 2019 Nov; 99():339-349. PubMed ID: 31499197
[TBL] [Abstract][Full Text] [Related]
18. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
Huang HC; Mallidi S; Liu J; Chiang CT; Mai Z; Goldschmidt R; Ebrahim-Zadeh N; Rizvi I; Hasan T
Cancer Res; 2016 Mar; 76(5):1066-77. PubMed ID: 26719532
[TBL] [Abstract][Full Text] [Related]
20. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
